Zoetis Inc. (ZTS)
After hours:
| Previous close | 150.95 |
| Open | 150.42 |
| Bid | 146.00 x 800 |
| Ask | 148.82 x 800 |
| Day's range | 148.04 - 152.03 |
| 52-week range | 147.77 - 249.27 |
| Volume | |
| Avg. volume | 1,681,677 |
| Market cap | 69.42B |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | 33.63 |
| EPS (TTM) | 4.41 |
| Earnings date | 02 Nov 2022 - 07 Nov 2022 |
| Forward dividend & yield | 1.30 (0.88%) |
| Ex-dividend date | 20 Jul 2022 |
| 1y target est | 228.73 |
- Business Wire
Zoetis Announces the Completion of its Acquisition of Jurox, a Leading Provider of Livestock and Companion Animal Products
PARSIPPANY, N.J. & RUTHERFORD, New South Wales, Australia, September 30, 2022--Zoetis Inc. (NYSE: ZTS) today announced it has completed the acquisition of Jurox, a privately held animal health company that develops, manufactures and markets a wide range of veterinary medicines for treating livestock and companion animals. Jurox’s operations are based in Australia, with additional regional offices in New Zealand, U.S., Canada and the UK. Financial terms of the transaction, which was announced in
- Business Wire
Zoetis to Host Webcast and Conference Call on Third Quarter 2022 Financial Results
PARSIPPANY, N.J., September 29, 2022--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 3, 2022. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2022 financial results and respond to questions from financial analysts during the call.
- Simply Wall St.
Here's Why Zoetis (NYSE:ZTS) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
